Metropolitan Life Insurance Co NY reduced its stake in MEDNAX Inc (NYSE:MD) by 1.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,118 shares of the company’s stock after selling 433 shares during the period. Metropolitan Life Insurance Co NY’s holdings in MEDNAX were worth $682,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of MD. Nordea Investment Management AB grew its holdings in MEDNAX by 41.5% in the first quarter. Nordea Investment Management AB now owns 2,411,506 shares of the company’s stock valued at $65,521,000 after purchasing an additional 707,038 shares during the last quarter. Cerebellum GP LLC grew its holdings in MEDNAX by 116.3% in the first quarter. Cerebellum GP LLC now owns 11,179 shares of the company’s stock valued at $304,000 after purchasing an additional 6,010 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in MEDNAX by 97.1% in the first quarter. Riverhead Capital Management LLC now owns 128,689 shares of the company’s stock valued at $3,496,000 after purchasing an additional 63,413 shares during the last quarter. Neuburgh Advisers LLC grew its holdings in MEDNAX by 15.0% in the first quarter. Neuburgh Advisers LLC now owns 89,540 shares of the company’s stock valued at $2,433,000 after purchasing an additional 11,660 shares during the last quarter. Finally, Trexquant Investment LP grew its holdings in MEDNAX by 13.8% in the first quarter. Trexquant Investment LP now owns 63,780 shares of the company’s stock valued at $1,733,000 after purchasing an additional 7,730 shares during the last quarter. Hedge funds and other institutional investors own 91.60% of the company’s stock.
Several analysts have weighed in on MD shares. Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Citigroup set a $47.00 price objective on Quanta Services and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, Jefferies Financial Group lowered from a “buy” rating to a “hold” rating in a research note on Thursday, April 11th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $38.36.
MEDNAX (NYSE:MD) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.05). The firm had revenue of $851.20 million during the quarter, compared to analysts’ expectations of $906.35 million. MEDNAX had a positive return on equity of 9.82% and a negative net margin of 1.05%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter last year, the business earned $0.89 earnings per share. On average, research analysts anticipate that MEDNAX Inc will post 3.08 EPS for the current fiscal year.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Featured Article: What is dollar cost averaging (DCA)?
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.